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Background
Data on the prevalence of human papillomavirus
(HPV) types in invasive cervical carcinoma (ICC) in
w o m e nw i t hH I Va r es c a r c eb u ta r ee s s e n t i a lt oe l u c i -
date the influence of immunity on the carcinogenicity
of different HPV types, and the potential impact of
prophylactic HPV vaccines in populations with high
HIV prevalence.
Objectives
To compare the prevalence of HPV types in ICC by
HIV status.
Methods
From 2007 to 2009, a multicentre case-case study was
conducted at two referral hospitals in Nairobi, Kenya, and
in Durban, South Africa. Women over 18 years of age
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Figure 1 Prevalence of human papillomavirus (HPV) in 225 women with cervical squamous cell carcinoma by HIV status and multiplicity of HPV
infection
1
10 HPV-negative women were excluded;
2Either 16 or 18 as single infection or in combination with any type as multiple type infection;
HPV: human papillomavirus; HRX: uncharacterized high-risk type; LR: low-risk.
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were obtained and tested for HPV DNA using GP5+/6
+-PCR methodology. The present analysis was limited to
the 235 squamous cell cancers (SCC) detected.
Results
We included 106 HIV-positive (mean age 40.8 years) and
129 HIV-negative women (mean age 45.7) with SCC.
Among HIV-positive women, the mean CD4 count was
334 cells/μL and 48.1% were on combined antiretroviral
therapy. HIV-positive women had many more multiple
HPV infections (21.6% of HPV-positive carcinomas)
compared to HIV-negative women (3.3%) (p <0.001) and
the proportion of multiple infections was inversely
related to CD4 level. An excess of HPV18 of borderline
statistical significance was found in HIV-positive com-
pared to HIV-negative women (Prevalence ratio (PR) =
1.9, 95% confidence interval (CI): 1.0-3.7, adjusted for
centre, age and multiplicity of infection). HPV16 and/or
18 prevalence combined, however, was similar in HIV-
positive (66.7%) and HIV-negative women (69.1%) (PR =
1.0, 95% CI: 0.9-1.2). No significant difference was found
for other HPV types (Figure 1).
Conclusions
Overall, our data suggest that current prophylactic HPV
vaccines against HPV16 and 18 may prevent similar
proportions of cervical SCC inH I V - p o s i t i v ea si nH I V -
negative women provided that vaccine-related protection
is sustained after HIV infection.
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